Zydus Pharmaceuticals (USA) Inc recalls Bromocriptine Mesylate Capsules
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- Failed Impurities/Degradation Specifications: Out of Specification (OOS) result reported for 2- Bromoergine impurity of Bromocriptine Mesylate Capsules.
- Products
-
- Bromocriptine Mesylate Capsules
- Where it was sold
-
Nationwide in the USA
Nationwide
- Units affected
- 36,624 bottles
- About this recall
- Bromocriptine Mesylate Capsules, USP, 5 mg, 30 Capsules per bottle, Rx Only. Manufactured by: Zydus Lifesciences Ltd., Ahmedabad, India. Distributed by: Zydus Pharmaceuticals, Pennington, NJ 08534. NDC 68382-110-06